COVID-19 in hematopoietic cell transplant recipients
Şuayıp Birinci(Ministry of Health), Sinem Namdaroğlu(Sağlık Bilimleri Üniversitesi), Mehmet Ali Erkurt(Inonu University), Tuba Hacıbekiroğlu(Sakarya University), Mehmet Hilmi Doğu, Burhan Turgut(Tekirdağ Namık Kemal University), Tuğçe Nur Yiğenoğlu(Ministry of Health), Kürşat Dal(S.B. Keçiören Eğitim ve Araştırma Hastanesi), Abdulkadir Baştürk(Selçuk University), İlhami Berber(Inonu University), Naim Ata(Ministry of Health), Mehmet Sinan Dal(Ministry of Health), Mustafa Mahir Ülgü(Ministry of Health), Osman Çelik(Ministry of Health), Abdullah Akünal(Ministry of Health), Semih Başçı(Ministry of Health), Fevzi Altuntaş, Serdal Korkmaz(Kayseri Eğitim ve Araştırma Hastanesi)
Cited by 31
Related Papers
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2019|383
The outcome of COVID‐19 in patients with hematological malignancy
|Journal of Medical Virology|2020|134
Cesarean section rates in Turkey 2018-2023: Overview of national data by using Robson ten group classification system
|Journal of Turkish Society of Obstetric and Gynecology|2023|41
Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors
|Journal of Oncology Pharmacy Practice|2020|40
Adoption rates of electronic health records in Turkish Hospitals and the relation with hospital sizes
|BMC Health Services Research|2020|40